Psych Investor retweeted
APPROACH Phase 3 Topline Study Results
$HELP
Link: ir.helus.com/static-files/1c…
Psych Investor retweeted
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
$HELP
ir.helus.com/news-releases/n…
Psych Investor retweeted
Helus Pharma today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 as an adjunctive treatment for adults with major depressive disorder.
Learn more: ir.helus.com/news-releases/n… ↩️
Psych Investor retweeted
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
$HELP
ir.helus.com/news-releases/n…
Psych Investor retweeted
Helus Pharma will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder.
Learn more: shorturl.at/1NF0m ↩️
Psych Investor retweeted
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
$HELP
globenewswire.com/news-relea…
Psych Investor retweeted
Study Tracks 3,000 Real-World Psychedelic Journeys - neurosciencenews.com/psychop… via @neurosciencenew
Psych Investor retweeted
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
$CMPS
ir.compasspathways.com/News-…
Psych Investor retweeted
LSD as a longevity therapy?
LSD pushes brain gene activity in the opposite direction of aging
In rodents, the effect was stronger than exercise
LSD activated gene networks involved in neuroplasticity and neuronal communication, and reduced amyloid-β damage
Psych Investor retweeted
Compass Files Psilocybin for TRD New Drug Application with FDA
This morning, Compass Pathways announced the submission of its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA).
Read more on our website: psychedelicalpha.com/news/br…
Psych Investor retweeted
From the @InvestorStream_ desk:
📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043
⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships
#biotech #health
youtube.com/shorts/SVMj5KlyA…
Psych Investor retweeted
🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043.
Read more: asx.api.cmfyapp.com/asx-rese…
#ASX $ENP #Biotech
Psych Investor retweeted
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
$CMPS
ir.compasspathways.com/News-…
Psych Investor retweeted
@Solvonis (LSE: SVNS) receives USPTO Notice of Allowance for its method-of-use patent covering ketamine across all behavioural addictions.
First priorities: binge eating and gambling disorders. Grant expected Q1 2027; term to May 2042. Investigational.
🔗solvonis.com/news/behavioura…
$SVNS
Psych Investor retweeted
Dr. Garcia-Romeu comments on new phase 2b research from Beckley Psytech Ltd on the shorter-acting effects of BPL-003 and its potential to help with treatment-resistant depression. newsweek.com/psychedelic-fro…
Psych Investor retweeted
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
$CMPS
ir.compasspathways.com/News-…
Psych Investor retweeted
This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission.
“Final NDA submission nearing completion”, the release states, “and will be filed in the next two weeks.”
Psych Investor retweeted
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston.
The fireside chat will be webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT.
Learn more and register for the webcast here: shorturl.at/y0yQw
Psych Investor retweeted
Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference
$HELP
ir.helus.com/news-releases/n…
Psych Investor retweeted
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
$CMPS
ir.compasspathways.com/News-…













